New User Account Set Up

If you do not have an account with the Digest, please click on "Submit to the Digest." By logging in with your UCLA Login ID (formerly known as BOL Login), a new account will automatically be generated. If you experience any difficulties, please send an email to our help desk:


If you have any questions or concerns, please email our help desk/support team: We are more than happy to address any questions or concerns regarding the Weekly Message Digest system you may have.

How do I subscribe?

If you have a mednet email account (, you should already be subscribed.

If you do not have a mednet email account or you are not receiving the Digest, please send an email to and we will add you to our list.

A5321: A Study for People Living with HIV with Low-Level Viremia

The UCLA CARE Center is conducting a research study (A5321) looking for persons living with HIV who are taking anti-HIV drugs, but whose HIV viral load is still sometimes detectable. Most participants will be seen every 6 months for about 7 years. We are investigating which factors play a role in controlling HIV over time:

  • Viral load and CD4 count when HIV treatment initiated
  • How long after initial HIV infection was ART initiated
  • Concentration of anti-HIV drugs detectable in blood, hair, and other fluid/tissue
  • Genetics

Eligibility Requirements:

  • Be HIV+
  • 18 years of age or older
  • Experiencing persistent low-level viremia* while on stable ART medications for a year or more
  • Have no active Hepatitis B or C infection, history of organ or bone marrow transplant, autoimmune disorder or a condition requiring steroid therapy
  • Be taking and planning to continue current anti-HIV medications


*low-level viremia is defined here as viral load 20-1500 copies/mL at least twice in the past 24 months, one of those times in the past 12 months, and *no* viral load results during that time period > 1500 c/mL.

Principal Investigator: Judith Currier, MD, MSc


Posting Information
This posting expired on February 24, 2022.
Posting Attachment: Download Attachment

Share this posting on social media!